###
中国临床研究:2023,36(11):1640-1644
本文二维码信息
码上扫一扫!
彩色多普勒超声联合血清HAS2和ADAM9诊断甲状腺微小乳头状癌的价值
(联勤保障部队第九一〇医院健康医学科,福建 泉州 362000)
Color Doppler ultrasound combined with serum HAS2 and ADAM9 in diagnosis of papillary thyroid microcarcinoma
(Department of Health Medicine, 910th Hospital of Joint Logistics Support Force, Quanzhou, Fujian 362000, China)
摘要
本文已被:浏览 209次   下载 186
投稿时间:2023-07-24   网络发布日期:2023-11-20
中文摘要: 目的 分析彩色多普勒超声(彩超)、血清透明质酸合酶2(HAS2)、去整合素金属蛋白酶9(ADAM9)及三者联合对甲状腺微小乳头状癌(PTMC)的诊断价值。方法 选取2020年10月至2022年10月在联勤保障部队第九一〇医院行手术治疗,且病理结果证实为PTMC的患者74例作为恶性组,选取同期术后病理结果为甲状腺良性结节的患者71例作为良性组。所有患者均行彩超检查;采用酶联免疫吸附法(ELISA)检测血清HAS2、ADAM9水平;采用Pearson法分析PTMC患者血清HAS2、ADAM9的相关性;采用受试者工作特征(ROC)曲线分析彩超、血清HAS2、ADAM9以及三者联合对PTMC的诊断价值。结果 恶性组和良性组结节在边界、内部回声、边缘、微钙化、纵横比以及声晕方面差异有统计学意义(P<0.05)。恶性组血清HAS2[(97.01±21.38) pg/mL vs (66.47±10.29) pg/mL, t=10.886, P<0.01]和ADAM9[(1.96±0.50 ) pg/mL vs (1.33±0.28) pg/mL, t=9.308, P<0.01]水平高于良性组。PTMC患者血清HAS2和ADAM9水平呈正相关(r=0.516,P<0.05)。血清HAS2、ADAM9诊断PTMC的AUC为0.929和0.924。三者联合在PTMC诊断中的准确度为85.52%,灵敏度为95.95%,高于单一检测。结论 彩超联合血清HAS2、ADAM9对PTMC具有较高的诊断价值,三者联合可提高诊断灵敏度。
Abstract:Objective To analyze the diagnostic value of color Doppler ultrasound, serum hyaluronic alkane synthase 2 (HAS2), a disintegrin and metalloproteinase domain 9 (ADAM9) and the combination in papillary thyroid microcarcinoma (PTMC). Methods Seventy-four patients who underwent surgical treatment in 910th Hospital of Joint Logistics Support Force from October 2020 to October 2022 and confirmed PTMC by pathological results were selected as the malignant group, and 71 patients with benign thyroid nodules by postoperative pathological results during the same period were selected as the benign group. All patients were examined by color Doppler ultrasound. The levels of serum HAS2 and ADAM9 were detected by enzyme-linked immunosorbent assay (ELISA). Pearson was applied to analyze the correlation between serum HAS2 and ADAM9 in patients with PTMC. The diagnostic value of color Doppler ultrasound, serum HAS2, ADAM9 and their combination in PTMC were evaluated using receiver operating characteristic (ROC) curve. Results There were statistically significant differences between malignant group and benign group in terms of boundary, internal echo, margin, microcalcification, aspect ratio and acoustic halo (P<0.05). The expression levels of serum HAS2 [(97.01±21.38) pg/mL vs (66.47±10.29) pg/mL, t=10.886, P<0.01] and ADAM9 [(1.96±0.50) pg/mL vs (1.33±0.28) pg/mL, t=9.308, P<0.01] in the malignant group were higher than those in the benign group. Serum levels of HAS2 and ADAM9 in PTMC patients were positively correlated (r=0.516, P<0.05). The area under the curve (AUC) for diagnosing PTMC using serum HAS2 and ADAM9 was 0.929 and 0.924, respectively. The combination of color Doppler ultrasound, serum HAS2 and ADAM9 had an accuracy of 85.52% and a sensitivity of 95.95% in diagnosing PTMC, which was higher than that of a single detection method. Conclusion Color Doppler ultrasound combined with serum HAS2 and ADAM9 has a high diagnostic value for PTMC, and their combination can improve diagnosis sensitivity.
文章编号:     中图分类号:    文献标志码:A
基金项目:
引用文本:
喻瑾, 许贤照, 于海霞, 杨天煌, 吴爱强.彩色多普勒超声联合血清HAS2和ADAM9诊断甲状腺微小乳头状癌的价值[J].中国临床研究,2023,36(11):1640-1644.

用微信扫一扫

用微信扫一扫